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Help Us Help You! 
Is this newsletter helpful to you?  
What articles would you like to see?  
Please contact Bridget Konz at 
bkonz@idph.state.ia.us or  
1-800-831-6293 ext. 7. 
Iowa VMBIP Planning Begins 
June 2007 
 
Iowa’s  
Immunization  
Registry Information  
System (IRIS)  
Enroll Today! 
 
Call the IRIS  
Help Desk at 
 1-800-374-3958  
for Enrollment Details or 
IRIS Questions. 
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The Vaccine Management Business 
Improvement Project (VMBIP) 
represents efforts of the Centers for 
Disease Control and Prevention (CDC) 
and the National Center for 
Immunization and Respiratory Diseases 
(NCIRD) to improve current vaccine 
management processes at the federal, 
state, and local levels.   
CDC/NCIRD is responsible for managing 
half of the nation’s pediatric vaccine 
supply, estimated at $11 billion in 
annual vaccine purchases.  Through 
the VMBIP project it is anticipated 
that $25 – $47 million will be saved 
nationally, allowing those saved 
funds to be used for other 
immunization priorities.  
There are three overall goals of the 
VMBIP project.  They are designed 
to identify opportunities and 
develop solutions toward improving 
vaccine efficiency, accountability, 
and the nation’s ability to respond 
to public health crises.  The specific 
goals of VMBIP are to: 
• Simplify processes for ordering, 
distributing, and managing vaccines 
in order to respond more quickly 
and effectively to public health 
crises related to disease outbreaks, 
vaccine shortages, and disruption of 
the vaccine supply. 
• Implement a more efficient vaccine 
supply system that will result in 
redirecting vital public health 
resources away from vaccine 
distribution and toward public health 
activities that will improve 
immunization coverage levels. 
• Enable the direct delivery of 
vaccines to providers.   
CDC projects that Iowa will “go live”  
and begin using VIMBIP in December 
2007.  As part of the implementation 
process, the Iowa Department of Public 
Health (IDPH) will begin to scale back its 
on-hand vaccine supply in late fall in 
preparation for the December “go live” 
date.  When Iowa “goes live” IDPH will 
no longer maintain or ship vaccine on-
site.  A third-party 
distributor, 
McKesson General 
Medical, will manage 
warehousing and 
distribution of all 
vaccines previously 
ordered through 
IDPH.  Currently, it 
is projected to take 
one week for 
McKesson to process 
and distribute 
vaccine orders.   
Prior to implementing VIMBIP in Iowa, 
one of the most important things 
providers can do is assess vaccine 
storage capacity.  IDPH plans to survey 
Vaccines for Children (VFC) providers to 
obtain a clearer picture of storage 
capacity in the state.  Once information 
on storage capacity is obtained it will be 
made available to McKesson for future 
use in vaccine ordering.   
Watch for further information from the 
IDPH Immunization Program regarding 
VMBIP.  IDPH will continue to share 
progress on this exciting project as we 
move forward.   
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Vaccine accountability is one of the 
VFC Programs highest priorities and 
is an essential Center for Disease  
Control and Prevention (CDC) grant  
requirement.  Iowa’s Immunization 
Program has a responsibility to the 
CDC for ensuring that vaccine loss 
and wastage is measured and  
minimized, that vaccines purchased 
with VFC funds are administered only 
to VFC-eligible children, and  
protecting the program against fraud 
and abuse.  
Of the many things a clinic does each 
day, vaccine accountability is one of 
the most important, preceded by 
proper vaccine storage and handling.   
 
The good news it that there are 
things that you can to do help assure 
vaccine accountability.     
VFC Vaccine Accountability 
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Vaccine Resource 
Recommendations for Storage and 
Handling of Selected Biologicals has 
been revised and published in  
January 2007.   
This booklet 
outlines the 
details of  
storing and 
handling of all 
vaccines.   
Information 
includes  
shipping  
requirements, 
condition 
upon arrival, storage requirements, 
shelf life, instructions for use, shelf 
live after opening, and special  
instructions.   
This booklet is available from the 
CDC Web page:    
http://www.cdc.gov/nip/publication
s/vac_mgt_book.htm 
The first thing is to be sure that 
doses of vaccine that are shipped 
are accurately accounted for in 
IRIS.  Without accepting vaccine in 
to IRIS, it is impossible to get an 
accurate inventory count.  When 
vaccine is entered 
into IRIS as a “give” 
it is automatically 
deducted from the 
clinic’s inventory and 
is reported to the 
VFC Program (doses 
administered data).   
Another important step you can 
take to ensure accountability is to 
be sure to give VFC vaccine only to 
VFC eligible children.  Using VFC 
vaccine on a private pay patient and 
then “paying back” the VFC Pro-
gram when then private stock is 
ordered or vise versa, should be the  
exception - not the rule.  This  
practice of exchanging vaccine can 
quickly lead to accountability issues.   
Completing Doses Administered Re-
ports, or for those clinics using 
IRIS completing data entry 
on time (within 2 weeks), is  
extremely important.   
These reports help us to 
track your clinic inventory 
and complete CDC reports.  
Vaccine inventory  
accountability and maintenance is a 
vital part of the VFC program.   
Without up-to-date inventories, 
Iowa can not expect to maintain an 
adequate vaccine supply to  
vaccinate all eligible children.   
 
The Immunization Program at the 
Iowa Department of Public Health 
wants to help make school  
enrollment easier!  
The view-only version of IRIS, called 
the Immunization Registry 
Information System – Certificate 
Search (IRIS-CS), 
is now available.  
IRIS-CS can help 
Iowa schools by  
allowing school  
personnel to 
search, view and 
print the Certificate 
of Immunization.  
The registry 
houses consolidated  
immunization information from 
healthcare providers into one reliable 
source. Using IRIS-CS will provide 
schools with required immunization 
information without added work on 
behalf of school personnel, parents, 
and healthcare providers. 
In May, all school superintendents 
received a letter from the  
Immunization Program with a New 
User Request Form.  Any interested 
schools can 
complete and 
return the form 
to the  
Immunization 
Program.  
The  
Immunization 
Program staff 
will enroll and 
assist schools 
regarding the IRIS-CS installation 
process.  For IRIS-CS questions, 
please call the IRIS Help Desk at  
1-800-374-3958. 
IRIS Certificate Search 
The view-only version 
of IRIS for Schools  is 
now available!  
IRIS-CS can help Iowa schools by 
allowing school personnel to 
search, view and print the  
Certificate of Immunization.  
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Spotlight Vaccine Preventable Disease:  
Varicella Zoster Virus 
Varicella Zoster Virus (VZV) is a DNA 
virus and is a member of the herpes 
virus group. Like other herpesvi-
ruses, VZV has the capacity to  
persist in the body after the primary 
infection as a latent infection. VZV 
persists in sensory nerve ganglia. 
Primary infection with VZV results in 
chickenpox. Herpes zoster (shingles) 
is the result of recurrent infection. 
The virus is believed to have a short 
survival time in the environment. 
Pathogenesis: VZV enters through 
the respiratory tract and  
conjunctiva. The virus is believed to 
replicate at the site of entry in the 
nasopharynx and in 
regional lymph 
nodes. A primary 
viremia occurs 4–6 
days after infection 
and disseminates 
the virus to other 
organs, such as the 
liver, spleen, and sensory ganglia. 
Further replication occurs in the  
viscera, followed by a secondary 
viremia, with viral infection of the 
skin.  Virus can be cultured from 
mononuclear cells of an infected 
person from 5 days before to 1 or 2 
days after the appearance of the 
rash. 
Transmission:  Infection with VZV 
occurs through the respiratory tract. 
The most common mode of  
transmission of VZV is believed to 
be person-to person from infected 
respiratory tract secretions.  
Transmission may also occur by  
respiratory contact with airborne 
droplets, or by direct contact or 
inhalation of aerosols from vesicular 
fluid of skin lesions of acute varicella 
or zoster. 
 
Clinical Features: The incubation 
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period is 14–16 days after exposure, 
with a range of 10–21 days. The  
incubation period may be prolonged 
in immunocompromised patients and 
those who have received  
postexposure treatment with a 
varicella antibody–containing product. 
Primary Infection (Chickenpox): 
A mild prodrome may precede the 
onset of a rash. Adults may have 1 to 
2 days of fever and malaise prior to 
rash onset, but in children the rash is 
often the first sign of disease.   
The rash is generalized and pruritic 
and progresses rapidly from macules 
to papules to vesicular 
lesions before crusting.  
The rash usually  
appears first on the 
head, then on the 
trunk, and then the  
extremities; the  
highest concentration 
of lesions is on the 
trunk (centripetal distribution).  
Lesions also can occur on mucous 
membranes of the oropharynx,  
respiratory tract, vagina, conjunctiva, 
and the cornea.  
Lesions are usually 1–4 mm in  
diameter. The vesicles are superficial 
and delicate and contain clear fluid on 
an erythematous base. Vesicles may 
rupture or become purulent before 
they dry and crust. Successive crops 
appear over several days, with lesions 
present in several stages of  
development. For example, macular 
lesions may be observed in the same 
area of skin as mature vesicles. 
Healthy children usually have 200–
500 lesions in 2 to 4 successive crops. 
The clinical course in healthy children 
is generally mild, with malaise,  
pruritus (itching), and temperature up 
to 102°F for 2–3 days.  
Adults may have more severe disease 
and have a higher incidence of  
complications. Respiratory and  
gastrointestinal symptoms are ab-
sent.  
Recovery from primary varicella  
infection usually results in lifetime 
immunity. In otherwise healthy  
persons, a second occurrence of 
chickenpox is not common, but it can 
happen, particularly in immunocom-
promised persons. As with other viral 
diseases, reexposure to natural (wild) 
varicella may lead to reinfection that 
boosts antibody titers without  
causing clinical illness or detectable 
viremia. 
Recurrent Disease (Herpes  
Zoster): Herpes zoster, or shingles,  
occurs when latent VZV reactivates 
and causes recurrent disease. The 
immunologic mechanism that  
controls latency of VZV is not well 
understood. However, factors  
associated with recurrent disease 
include aging, immunosuppression, 
intrauterine exposure to VZV, and 
having had varicella at a young age 
(younger than 18 months). In  
immunocompromised persons, zoster 
may disseminate, causing generalized 
skin lesions and central nervous  
system, pulmonary, and hepatic  
involvement. The vesicular eruption 
of zoster generally occurs unilaterally 
in the distribution of a sensory nerve. 
Most often, this involves the trunk or 
the fifth cranial nerve. Two to four 
days prior to the eruption, there may 
be pain and paresthesia in the  
involved area. There are few  
systemic symptoms. 
Complications of Varicella:  Rare 
complications of varicella include  
aseptic meningitis, transverse  
myelitis, Guillain-Barré syndrome,  
Continued on page 4 
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In February 2007, CDC received notice 
from Merck & Co., Inc. that, because of 
smaller-than-expected amounts of 
varicella-zoster virus (VZV) in its  
recently manufactured bulk vaccine, the 
company was prioritizing production of 
varicella (Varivax®) and zoster 
(Zostavax®) vaccines over production of 
MMR-V vaccine (ProQuad®).  
In May 2007, CDC received further  
notice from Merck that current order 
projections indicate ProQuad will be 
unavailable beginning in July 2007.  
Although timing will depend on market 
demand, there may be extensive back 
orders for the next few months. After 
depletion of the existing supply, 
ProQuad will not be available 
for the remainder of 2007. 
Merck is requesting that customers 
begin transitioning from ProQuad to 
MMR and Varivax at their earliest 
convenience.  
Merck expects to meet demands for 
Varivax and MMR to fully support 
the recommended immunization 
schedule. This will allow for  
continued use of varicella vaccine 
for the following age groups:  
Routine 2-dose schedule for  
children aged 12--15 months and 4-
-6 years; Catch-up vaccination with 
the second dose for children or  
adolescents who received only 1 
dose; Vaccination with 2 doses for 
other children, adolescents, and 
adults without evidence of 
immunity.   
 
The supply of Zostavax is expected 
to be adequate for routine  
vaccination of adults aged >60 
years. Address questions regarding 
the supply of these Merck products 
to Merck's National Service Center 
at 800-637-2590. Updates on  
vaccine shortages and delays are 
available from CDC at 
http://www.cdc.gov/nip/news/shor
tages/default.htm.  
Continued from page 3:    
thrombocytopenia, hemorrhagic 
varicella, purpura fulminans,  
glomerulonephritis, myocarditis,  
arthritis, orchitis, uveitis, iritis, and 
hepatitis. 
The risk of  
complications 
from varicella 
varies with age. 
Complications are 
infrequent among 
healthy children. 
They occur much 
more frequently 
in persons older than 15 years of age 
and infants younger than 1 year of 
age.  
For instance, among children 1–14 
years of age, the fatality rate of 
varicella is approximately 1 per 
100,000 cases, among persons 15–19 
years, it is 2.7 per 100,000 cases, and 
among adults 30–49 years of age, 
25.2 per 100,000 cases. Adults ac-
count for only 5% of reported cases of 
varicella but approximately 35% of 
mortality. 
 
Complications of Zoster:  
Postherpetic neuralgia, or pain in the 
area of the occurrence that persists 
after the lesions have resolved, is a 
distressing complication of zoster. 
There is cur-
rently no ade-
quate  
therapy avail-
able.  
Postherpetic  
neuralgia may 
last a year or 
longer after the 
episode of  
zoster. Ocular nerve and other organ 
involvement with zoster can occur, 
often with severe sequelae. 
 
Varicella Vaccine: Varicella virus 
vaccine is recommended for all  
children without contraindications at 
12 through 15 months of age. The 
vaccine may be given to all children 
at this age regardless of prior history 
of varicella. However, vaccination is 
not necessary for children with  
reliable histories of chickenpox.   
Breakthrough Varicella Disease: 
Immunity appears to be long last-
ing, and is probably permanent in 
the majority of vaccinees. However, 
approximately 1% of vaccines per 
year have developed breakthrough 
infections (i.e., developed varicella 
disease even though they had  
responded to the vaccine).  
Breakthrough infection is  
significantly milder, with fewer  
lesions (generally fewer than 50), 
many of which are maculopapular 
rather than vesicular. Most persons 
with breakthrough infection do not 
have fever. 
 
Zoster Vaccine:  Zoster vaccine is 
approved by FDA for persons 60 
years and older. A single dose of 
zoster vaccine is recommended for 
adults 60 years of age and older 
whether or not they report a prior 
episode of herpes zoster. 
If you have questions regarding  
either varicella or zoster vaccines 
please contact the Immunization 
Program at 1-800-831-6293.  
Varicella Zoster Virus, Continued 
Vaccine Recommendations  
Routine varicella vaccination at 12-15 
months and 2nd dose at 4-6 years.  Mini-
mum interval for children less than 13 
years of age is 3 months.  
Routine single zoster vaccination for 
adults 60 years of age and older  
regardless of previous zoster episode.  
Supply of Vaccines Containing Varicella-Zoster Virus 
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Pneumococcal Conjugate Vaccine 
Required for Entry into Licensed Child Care  
House file 245 was signed by  
Governor Culver on March 9, 2007.  
This bill requires that a child show 
“evidence of adequate immuniza-
tion against haemophilus influenza 
B and invasive pneumococcal  
disease” prior to enrollment in any 
licensed child care center.   
The Iowa Immunization Program 
will collaborate with its  
advisory group to write  
Administrative Rules for this bill.  
Watch for new requirements to be 
in effect in 2008.   
Invasive pneumococcal disease is 
important because the bacterium, 
streptococcus pneumoniae, causes 
acute bacterial infection. The 
bacterium, also called  
pneumococcus, was first  
isolated by Pasteur in 1881 
from the saliva of a patient 
with rabies. The major  
clinical syndromes of  
pneumococcal disease are 
pneumonia, bacteremia, and 
meningitis.  Efforts to  
develop effective 
 pneumococcal vaccines  
began as early as 1911. With 
the advent of penicillin in the 
1940s, interest in the vaccine  
declined, until it was  
observed that many patients 
died despite antibiotic  
treatment. 
Bacteremia without a known 
site of infection is the most 
common invasive clinical 
presentation of pneumococ-
cal infection among children 
2 years of age and younger, 
accounting for approximately 
70% of invasive disease in 
this age group.  
Bacteremic pneumonia  
accounts for 12%–16% of invasive 
pneumococcal disease among  
children aged 2 years and younger.  
With the decline of invasive Hib 
disease, S. pneumoniae has  
become the leading cause of 
 bacterial meningitis among U.S. 
children younger than 5 years of 
age.  Before routine use of pneumo-
coccal conjugate vaccine, children 
younger than 1 year had the highest 
rates of pneumococcal meningitis,  
approximately 10 cases per 100,000 
population while the burden of  
pneumococcal disease among  
children younger than 5 years of age 
remained significant.  
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An estimated 17,000 cases of invasive 
disease occurred each year, of which 
13,000 were bacteremia without a 
known site of infection, and about 700 
were meningitis. An estimated 200 
children died each year from invasive 
pneumococcal disease. Although not 
considered an invasive disease, an 
estimated 5 million cases of acute  
otitis media occurred each year 
among children younger than 5 years 
of age. 
If you have questions on this bill or 
the Administrative Rules process 
please contact Marnell Kretschmer at  
1-800-831-6293, ext. 3.  
 
Recommendations for the Routine Administration of Pneumococcal Vaccine  
(Pneumococcal Conjugate Vaccine - Prevnar)  
• All children younger than 24 months of age and children age 24–59 months 
with a high-risk medical condition should be routinely vaccinated with PCV7. 
The primary series beginning in infancy consists of three doses routinely given at 2, 
4, and 6 months of age. 
• A fourth (booster) dose is recommended at 12–15 months of age. 
• PCV7 should be administered at the same time as other routine childhood  
immunizations, using a separate syringe and injection site. 
• For children younger than 12 months of age at vaccination, the minimum interval 
between doses is 4 weeks. Doses given at 12 months of age and older should be 
separated by at least 8 weeks. 
• Unvaccinated children 7 months of age and older do not require a full series of four 
doses. The number of doses needed to complete the series depends on the child’s 
current age. Unvaccinated children aged 7–11 months should receive two doses of 
vaccine at least 4 weeks apart, followed by a booster dose at age 12–15 months. 
• Unvaccinated children aged 12–23 months should receive two doses of vaccine at 
least 8 weeks apart. Previously unvaccinated healthy children 24–59 months of age 
should receive a single dose of PCV7. Unvaccinated children 24–59 months of age 
with sickle cell disease, asplenia, HIV infection, chronic illness, cochlear implant, or 
immunocompromising conditions should receive two doses of PCV7 separated by at 
least 8 weeks. 
• PCV7 is not routinely recommended for persons older than 59 months of age. 
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Useful Web Sites for  
Immunization Providers 
 
Centers for Disease Control and Prevention  
National Immunization Program    
www.cdc.gov/nip   
 
Iowa Immunization Program 
www.idph.state.ia.us/adper/immunization.asp 
 
The Immunization Action Coalition  
www.immunize.org  
 
Children’s Hospital of Philadelphia    
www.vaccine.chop.edu  
 
American Academy of Pediatrics   
www.aap.org  
 
Every Child By Two 
www.ecbt.org 
 
Food and Drug Administration - Vaccines 
www.fda.gov/cber/vaccines.htm 
 
Severe Weather Events 
Is Your Vaccine Supply Safe?  
You Call the Shots Training Module  
Hepatitis A Module is Now Available!   
This web based training course is offered by the CDC at 
the Web page below.  CEUs for nurses are available 
upon completion of the courses.  Check it out! 
Now available: Understanding the Basics:  General  
Recommendations on Immunization, Diphtheria,  
Tetanus and Pertussis; Polio; HIB; and Influenza 
Other modules under development include:  Hepatitis B, 
MMR, Meningococcal, Overview of Bioterrorism, 
Pneumococcal, Vaccine Administration Practice, and 
Varicella 
http://www.cdc.gov/nip/ed/youcalltheshots.htm 
Floods, tornados and early spring ice 
storms can all have a devastating 
effect on resources such as 
power and transportation.  
When those resources are 
impacted so is normal  
vaccine storage and 
handling.  Emergency plans 
to protect vaccine in the 
event of severe weather are 
vital.     
Nationwide, the Vaccines 
for Children (VFC) Program 
maintains inventories in the 
field valued at over $11 billion.  
To protect the national vaccine 
inventory and minimize potential 
monetary loss from natural disasters 
or other emergencies, immunization 
facilities should develop a Written 
Emergency Plan to safeguard  
vaccine inventories. 
Emergency procedures should  
address vaccine protection and/or 
retrieval.  When providers have  
reasonable cause to believe emerging 
conditions 
will disrupt 
vaccine  
operations, 
emergency 
procedures 
should be 
implemented 
in advance of 
the event.    
Before the emergency, providers 
should identify an alternative storage 
facility (hospital, packing plant, state 
depot,) with back-up power (a  
generator) where the vaccine can be 
properly stored and monitored; insure 
availability of staff to pack and move 
the vaccine; maintain appropriate 
packing materials (insulated  
containers, ice packs, dry ice for 
Varicella/MMR vaccine); and insure a 
means of transport for the vaccine to 
the secure storage facility. 
Whenever possible, facilities should 
suspend vaccination activities  
BEFORE the onset of emergency  
conditions to allow sufficient time for 
packing and transporting vaccine.  
The Immunization Program has  
developed a Vaccine Storage and 
Handling Guidelines template,  
Emergency Response Plan, &  
Worksheet to assist your facility with 
the planning process.  These  
documents are available on the  
Immunization Program Web page at:  
www.idph.state.ia.us/adper/common/
pdf/immunization/storage_handling_
guide.pdf)  
www.idph.state.ia.us/adper/common/
pdf/immunization/emergency_respon
se.pdf   
Questions? Please contact the  
Immunization Program at  
1 -800-831-6293 ext. 2.   
